Click Here to
News, Updates,
& More
Stay Up
to Date

JHOP - April 2020 Vol 10, No 2

Ovarian cancer has an annual incidence of 11.4 per 100,000 women in the United States, with a 5-year overall survival of 47.6% for all stages.1 In patients with fallopian tube or primary peritoneal ovarian cancer, a platinum-based (ie, carboplatin, cisplatin) regimen is the chemotherapy of choice in the metastatic or the adjuvant setting.2
Febrile neutropenia requires quick intervention with antipseudomonal beta-lactam antibiotics, such as piperacillin-tazobactam. Previous studies suggest that extended infusions may improve outcomes. The findings in this study show that use of extended infusions of piperacillin-tazobactam led to similar results as intermittent infusions, including defervescence, duration of antibiotic use, mortality, and antibiotic failure.
The sudden price increase of injectible calcitonin in 2015 prompted one institution to implement formulary restriction criteria to ensure optimal and cost-effective usee. The findings of this study show that using specific formulary restrictions and use criteria of calcitonin can appropriately reduce utilization and cost without affecting patient outcomes.
On April 3, 2020, the Association for Value-Based Cancer Care (AVBCC) held a webcast with healthcare experts representing major industry stakeholders to address the impact of the COVID-19 pandemic on oncology delivery systems and the management of patients with cancer.
Nivolumab is now approved for every 4-week dosing. Nivolumab 480-mg dosing may have led to a more severe case of transaminitis than the every 2-week dosing in this patient with non–small-cell lung cancer, who had severe transaminitis 21 days after administration of the first dose. The steroid-refractory nature of this patient’s transaminitis, and the unclear current recommendations for infection prophylaxis, complicated the management of this patient’s autoimmune reaction.
Patients undergoing hematopoietic stem-cell transplantation (HSCT) often receive highly emetogenic, multiday conditioning chemotherapy. Many patients experience nausea and vomiting, which may negatively affect quality of life, despite receiving triple therapy with dexamethasone, a neurokinin-1 (NK-1) receptor antagonist, and serotonin receptor antagonists (5-HT3).
The combination of atezolizumab immunotherapy plus bevacizumab improves survival as well as significantly delaying deterioration in quality of life compared with the current standard of the targeted therapy sorafenib in the treatment of patients with unresectable hepatocellular carcinoma (HCC).
Page 1 of 2
Results 1 - 10 of 12